Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMAGNASDAQ:CBAYNASDAQ:COLLNASDAQ:CTMXNASDAQ:PTGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMAGAMAG Pharmaceuticals$13.75$13.74$4.41▼$13.80$477.47M0.89950,664 shsN/ACBAYCymaBay Therapeutics$32.48$32.44$7.26▼$32.50$3.73B0.324.11 million shs73 shsCOLLCollegium Pharmaceutical$30.30+2.5%$28.98$23.23▼$42.29$950.14M0.64398,219 shs267,653 shsCTMXCytomX Therapeutics$2.36+4.0%$1.93$0.40▼$3.10$183.01M2.052.19 million shs2.57 million shsPTGXProtagonist Therapeutics$50.21-9.2%$48.97$32.50▼$60.60$3.43B2.26890,675 shs1.51 million shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMAGAMAG Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CBAYCymaBay Therapeutics0.00%0.00%0.00%0.00%0.00%COLLCollegium Pharmaceutical-1.20%-1.04%+0.61%+0.61%-8.17%CTMXCytomX Therapeutics+0.89%+5.09%-9.92%+291.38%+86.07%PTGXProtagonist Therapeutics-0.75%+3.58%+16.90%+17.90%+59.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMAGAMAG PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACBAYCymaBay TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACOLLCollegium Pharmaceutical4.0185 of 5 stars3.41.00.03.01.60.82.5CTMXCytomX Therapeutics4.2104 of 5 stars3.51.00.04.72.41.71.3PTGXProtagonist Therapeutics1.7412 of 5 stars3.51.00.00.01.42.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMAGAMAG Pharmaceuticals 0.00N/AN/AN/ACBAYCymaBay Therapeutics 0.00N/AN/AN/ACOLLCollegium Pharmaceutical 2.75Moderate Buy$43.7544.39% UpsideCTMXCytomX Therapeutics 3.00Buy$5.33125.99% UpsidePTGXProtagonist Therapeutics 3.00Buy$66.1031.65% UpsideCurrent Analyst Ratings BreakdownLatest COLL, CBAY, AMAG, CTMX, and PTGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025PTGXProtagonist TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$72.006/3/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.005/19/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/15/2025CTMXCytomX TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$2.50 ➝ $5.005/15/2025CTMXCytomX TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$5.00 ➝ $5.005/12/2025CTMXCytomX TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$5.00 ➝ $6.005/9/2025COLLCollegium PharmaceuticalPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$36.00 ➝ $37.004/14/2025CTMXCytomX TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$3.25 ➝ $2.504/10/2025PTGXProtagonist TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.004/9/2025COLLCollegium PharmaceuticalNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMAGAMAG Pharmaceuticals$327.75M1.46N/AN/A$7.37 per share1.87CBAYCymaBay Therapeutics$31.07M119.92N/AN/A$2.58 per share12.59COLLCollegium Pharmaceutical$631.45M1.54$12.63 per share2.40$7.10 per share4.27CTMXCytomX Therapeutics$138.10M1.38$0.38 per share6.27($0.01) per share-236.00PTGXProtagonist Therapeutics$434.43M7.16$4.10 per share12.24$11.33 per share4.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMAGAMAG Pharmaceuticals-$466.46M-$6.88N/A76.39N/A-74.93%-16.92%-5.96%N/ACBAYCymaBay Therapeutics-$105.37M-$0.97N/AN/AN/AN/A-50.72%-31.04%N/ACOLLCollegium Pharmaceutical$69.19M$1.2224.845.03N/A6.61%99.08%15.14%8/6/2025 (Estimated)CTMXCytomX Therapeutics$31.87M$0.484.92N/AN/A28.22%-553.71%32.21%8/14/2025 (Estimated)PTGXProtagonist Therapeutics$275.19M$0.7566.95N/AN/A27.04%9.22%8.31%8/5/2025 (Estimated)Latest COLL, CBAY, AMAG, CTMX, and PTGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025CTMXCytomX Therapeutics$0.18$0.27+$0.09$0.27$35.42 million$50.92 million5/8/2025Q1 2025COLLCollegium Pharmaceutical$1.50$1.49-$0.01$0.07$174.96 million$177.76 million5/6/2025Q1 2025PTGXProtagonist Therapeutics-$0.50-$0.19+$0.31-$0.19$30.44 million$28.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMAGAMAG PharmaceuticalsN/AN/AN/AN/AN/ACBAYCymaBay TherapeuticsN/AN/AN/AN/AN/ACOLLCollegium PharmaceuticalN/AN/AN/AN/AN/ACTMXCytomX TherapeuticsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMAGAMAG Pharmaceuticals1.131.751.45CBAYCymaBay TherapeuticsN/A10.9610.96COLLCollegium Pharmaceutical3.301.081.01CTMXCytomX TherapeuticsN/A1.731.73PTGXProtagonist TherapeuticsN/A17.2517.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMAGAMAG PharmaceuticalsN/ACBAYCymaBay Therapeutics95.03%COLLCollegium PharmaceuticalN/ACTMXCytomX Therapeutics67.77%PTGXProtagonist Therapeutics98.63%Insider OwnershipCompanyInsider OwnershipAMAGAMAG Pharmaceuticals12.73%CBAYCymaBay Therapeutics7.00%COLLCollegium Pharmaceutical2.51%CTMXCytomX Therapeutics6.60%PTGXProtagonist Therapeutics4.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMAGAMAG Pharmaceuticals44034.73 millionN/AOptionableCBAYCymaBay Therapeutics101114.72 million106.69 millionOptionableCOLLCollegium Pharmaceutical21032.13 million31.33 millionOptionableCTMXCytomX Therapeutics17080.62 million75.30 millionOptionablePTGXProtagonist Therapeutics12061.98 million58.95 millionOptionableCOLL, CBAY, AMAG, CTMX, and PTGX HeadlinesRecent News About These CompaniesProtagonist Therapeutics (NASDAQ:PTGX) Trading Down 7.2% - What's Next?July 1 at 4:10 PM | marketbeat.comProtagonist Enters Obesity Fray With Triple-G Pill, Eyeing 2026 Clinical StartJuly 1 at 12:43 PM | biospace.comBProtagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for ObesityJune 30 at 4:40 PM | usatoday.comCan Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?June 30 at 4:40 PM | msn.comPTGX Protagonist Therapeutics, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comProtagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development CandidateJune 26, 2025 | accessnewswire.comAProtagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia VeraJune 24, 2025 | msn.comProtagonist Therapeutics’ SWOT analysis: biotech stock poised for growthJune 20, 2025 | investing.comCiti Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs OpportunityJune 20, 2025 | msn.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Position Lifted by Exchange Traded Concepts LLCJune 19, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Now Covered by CitigroupJune 17, 2025 | marketbeat.comAssenagon Asset Management S.A. Sells 7,367 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)June 17, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Buy" from BrokeragesJune 14, 2025 | marketbeat.comGAMMA Investing LLC Raises Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)June 13, 2025 | marketbeat.comArturo Md Molina Sells 10,000 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) StockJune 12, 2025 | insidertrades.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Insider Arturo Md Molina Sells 10,000 SharesJune 11, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Upgraded to "Hold" at Wall Street ZenJune 8, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Sells 6,008 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)June 7, 2025 | marketbeat.comShort Interest in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Decreases By 13.6%June 5, 2025 | marketbeat.com9 Analysts Assess Protagonist Therapeutics: What You Need To KnowJune 4, 2025 | benzinga.comProtagonist Therapeutics' (PTGX) "Buy" Rating Reaffirmed at HC WainwrightJune 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeTesla Bulls and Bears Collide: What Investors Should KnowBy Sam Quirke | June 18, 2025View Tesla Bulls and Bears Collide: What Investors Should KnowCOLL, CBAY, AMAG, CTMX, and PTGX Company DescriptionsAMAG Pharmaceuticals NASDAQ:AMAGAMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.CymaBay Therapeutics NASDAQ:CBAYCymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.Collegium Pharmaceutical NASDAQ:COLL$30.30 +0.73 (+2.47%) Closing price 04:00 PM EasternExtended Trading$30.30 0.00 (-0.02%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.CytomX Therapeutics NASDAQ:CTMX$2.36 +0.09 (+3.96%) Closing price 04:00 PM EasternExtended Trading$2.35 -0.01 (-0.64%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Protagonist Therapeutics NASDAQ:PTGX$50.21 -5.06 (-9.16%) Closing price 04:00 PM EasternExtended Trading$50.24 +0.02 (+0.05%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.